The Future of EU HTA: How Pharmaceutical Companies Can Prepare for the New Process

The Future of EU HTA: How Pharmaceutical Companies Can Prepare for the New Process

Create your strategy now for successfully navigating the new processes for The HTA Regulation (HTAR) beginning in 2025, which aim to enable development of a joint perspective on clinical aspects of drugs, in vitro diagnostics (IVDs), and high-risk medical devices.

Download your free white paper from Citeline’s Scrip, presented in partnership with IQVIA for analysis of:

  • The future of EU HTA
  • HTA at the EU level
  • Stakeholder concerns: complexity, timeframe, lack of involvement and disconnection
  • Improved access or layering of processes?
  • How to get ready for 2025
  • What the future will bring